Antihypertensive effect of a fixed-dose combination of losartan / hydrochlorothiazide in patients with uncontrolled hypertension: A multicenter study

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 269-278

  Hosoya, Tatsuo ^a   Kuriyama, Satoru ^a,b   Ohno, Iwao ^a   Kawamura, Tetsuya ^a   Ogura, Makoto ^a   Ikeda, Masato ^a   Ishikawa, Masahiro ^a,c   Hayashi, Fumihiro ^a,d   Kanai, Tatsuya ^e   Tomonari, Haruo ^f   Soejima, Michimasa ^g   Akaba, Kiyoaki ^h   Tokudome, Goro ^a,d  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c Kawaguchi Medical Center   (Japan)

^d Tokyu Hospital   (Japan)

^e Kanai Naika Clinic   (Japan)

^f Tomonari Clinic   (Japan)

^g Soejima Clinic   (Japan)

^h Akaba Clinic   (Japan)

Author keywords

Albuminuria; BNP; Hydrochlorothiazide; Hypertension; Losartan

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRESCRIPTION; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CREATININE; DRUG COMBINATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERURICEMIA; JAPAN; LOSARTAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URIC ACID; YOUNG ADULT;

EID: 84863724655     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0564-4     Document Type: Article

References (31)

1. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-92.
2. Ohkubo T, Obara T, Funahashi J, Kikuya M, Asayama K, Metoki H, Oikawa T, Takahashi H, Hashimoto J, Totsune K, Imai Y. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens Res. 2004;27:755-63.
3. Waeber B. Achieving blood pressure targets in the management of hypertension. Blood Press Suppl. 2001;2:6-12.
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
5. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim- Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, on behalf of The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
6. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sower J. Preserving renal function on adults with hypertension ans diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-61.
7. Kita T, Yokota N, Ichiki Y, Ayabe T, Etoh T, Tamaki N, Kato J, Eto T, Kitamura K. One-year effectiveness and safety of openlabel losartan/ hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res. 2010;33:320-5.
8. Enomoto A, Kimura H, Chairongudua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate exchanger that regulates blood urate levels. Nature. 2002;417:447-52.
9. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URAT-1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834-8.
10. Frohlich ED, Grim C, Labarthe DR, Maxell MH, Perloff D, Weidman WH. Recommendation for human blood pressure determination by sphygmomanometers. Hypertension. 1988;11: 209A-22A.
11. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res. 2006;29:143-51.
12. Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-Type diuretic use. Arch Intern Med. 2010;170:851-8.
13. Ando K, Isshiki M, Takahashi K. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. Hypertens Res. 2009;32:748-52.
14. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health. Int J Epidemiol. 2009;38:791-813.
15. Drenjančević-Perić I, Jelaković B, Lombard JH, Kunert MP, Kibel A, Gros M. High-salt diet and hypertension: focus on the renin-Angiotensin system. Kidney Blood Press Res. 2011;34:1-11.
16. Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens. 2010;24:739-48.
17. Liou YS, Ma T, Tien L, Lin CM, Jong GP. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new onset diabetes: A retrospective longitudinal cohort study. Hypertens Res. 2009;32:496-9.
18. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-6.
19. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97.
20. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.
21. Amery A, Brixko P, Clement D, De Schaepdryver A, Fagard R, Forte J, Henry JF, Leonetti G, O'Malley K, Strasser T, Birkenhäger W, Bulpitt C, Deruyttere M, Dollery C, Forette F, Hamdy R, Joossens JV, Lund-Johansen P, Petrie J, Tuomilehto J, Williams B. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet. 1985;325:1349-54.
22. Beckett NS, Ch B, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.
23. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-40.
24. Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, for the COPE Trial Group. Prevention of cardiovascular events with calcium antagonist-based combination therapies in patients with hypertension: A randomized controlled trial-combination therapy of hypertension to prevent cardiovascular events (COPE) trial (abstract). Presented at the International Society of Hypertension in Vancouver, 2010.
25. Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens. 2008;10(6):477-84.
26. Uzu T, Sakaguchi M, Yokomaku Y, Kume S, Kanasaki M, Isshiki K, Araki S, Sugimoto T, Koya D, Haneda M, Kashiwagi A. Effect of high salt intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol. 2009;13:300-6.
27. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
28. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe- Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
29. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595-600.
30. Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium- channel blocker. Am J Hypertens. 2010. doi:10.1038/ajh. 2010.240.
31. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving H-H, Grobbee DE, Shahnas S, Zeeuw ME, Heerspink HJL. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial. Hypertension. 2011;58: 2-7.